Alessandro Morabito

Summary

Country: Italy

Publications

  1. doi request reprint Systemic treatment of gastric cancer
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
    Crit Rev Oncol Hematol 70:216-34. 2009
  2. ncbi request reprint Bevacizumab in non small cell lung cancer: development, current status and issues
    C Sandomenico
    Thoraco Pulmonary Department, National Cancer Institute, Naples, Italy
    Curr Med Chem 19:961-71. 2012
  3. doi request reprint Vandetanib: An overview of its clinical development in NSCLC and other tumors
    A Morabito
    Medical Oncology, Thoraco Pulmonary Department, National Cancer Institute, Napoli, Italy
    Drugs Today (Barc) 46:683-98. 2010
  4. pmc Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial
    Francesco Nuzzo
    National Cancer Institute, Via M, Semmola, 80131 Napoli, Italy
    BMC Cancer 11:75. 2011
  5. doi request reprint Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial
    Emanuela Rossi
    Clinical Trials Unit, National Cancer Institute of Naples, Via Mariano Semmola, 80131, Napoli, Italy
    J Clin Oncol 27:3192-7. 2009
  6. ncbi request reprint Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial
    Francesco Nuzzo
    National Cancer Institute, Naples, Italy
    Crit Rev Oncol Hematol 66:171-80. 2008
  7. doi request reprint Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Oncologist 14:378-90. 2009
  8. doi request reprint Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    J Thorac Oncol 7:1830-44. 2012
  9. doi request reprint Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:233-42. 2012
  10. doi request reprint Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    Crit Rev Oncol Hematol 71:233-41. 2009

Collaborators

Detail Information

Publications34

  1. doi request reprint Systemic treatment of gastric cancer
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
    Crit Rev Oncol Hematol 70:216-34. 2009
    ..Finally, the results of ongoing clinical trials on a number of new molecular-targeted drugs should confirm their role in gastric cancer...
  2. ncbi request reprint Bevacizumab in non small cell lung cancer: development, current status and issues
    C Sandomenico
    Thoraco Pulmonary Department, National Cancer Institute, Naples, Italy
    Curr Med Chem 19:961-71. 2012
    ..The identification of predictive factors of efficacy would be relevant for the optimal use of the drug, but to date we have no conclusive data in this direction...
  3. doi request reprint Vandetanib: An overview of its clinical development in NSCLC and other tumors
    A Morabito
    Medical Oncology, Thoraco Pulmonary Department, National Cancer Institute, Napoli, Italy
    Drugs Today (Barc) 46:683-98. 2010
    ..The results of ongoing trials in untreated patients with advanced NSCLC and other tumors should better define the optimal clinical application of vandetanib...
  4. pmc Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial
    Francesco Nuzzo
    National Cancer Institute, Via M, Semmola, 80131 Napoli, Italy
    BMC Cancer 11:75. 2011
    ..To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer...
  5. doi request reprint Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial
    Emanuela Rossi
    Clinical Trials Unit, National Cancer Institute of Naples, Via Mariano Semmola, 80131, Napoli, Italy
    J Clin Oncol 27:3192-7. 2009
    ..CONCLUSION Adjuvant letrozole and tamoxifen result in significantly distinct endocrine effects. Such differences can explain the higher efficacy of letrozole as compared with tamoxifen...
  6. ncbi request reprint Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial
    Francesco Nuzzo
    National Cancer Institute, Naples, Italy
    Crit Rev Oncol Hematol 66:171-80. 2008
    ..In conclusion, weekly docetaxel appears to be less toxic than CMF in terms of hematological toxicity...
  7. doi request reprint Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Oncologist 14:378-90. 2009
    ..Ongoing phase II and III clinical trials will better define the appropriate schedule, the optimal setting of evaluation, and the safety of long-term use of vandetanib...
  8. doi request reprint Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Naples, Italy
    J Thorac Oncol 7:1830-44. 2012
    ..The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here...
  9. doi request reprint Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    J Thorac Oncol 7:233-42. 2012
    ..Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence...
  10. doi request reprint Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    Crit Rev Oncol Hematol 71:233-41. 2009
    ..Data were collected between April and September 2005...
  11. doi request reprint Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Eur J Cancer 46:735-43. 2010
    ..The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival...
  12. pmc Gefitinib in non small cell lung cancer
    Raffaele Costanzo
    Medical Oncology Unit, Thoraco Pulmonary Department, National Cancer Institute, 80131 Napoli, Italy
    J Biomed Biotechnol 2011:815269. 2011
    ..The results of these trials have demonstrated the efficacy of gefitinib that can be now considered as the standard first-line treatment of patients with advanced NSCLC harbouring activating EGFR mutations...
  13. pmc Is human hepatocellular carcinoma a hormone-responsive tumor?
    Massimo Di Maio
    Medical Oncology, N Giannettasio Hospital, Rossano 87068, Italy
    World J Gastroenterol 14:1682-9. 2008
    ..Negative results have been obtained also with anti-androgen therapy. In conclusion, there is no robust evidence to consider HCC a hormone-responsive tumor. Hormonal treatments should not be part of the current management of HCC...
  14. ncbi request reprint Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer
    Emanuela Rossi
    Clinical Trials Unit, National Cancer Institute of Naples, Via Mariano Semmola, 80131, Napoli, Italy
    J Clin Oncol 26:264-70. 2008
    ....
  15. ncbi request reprint Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer
    Massimo Di Maio
    Medical Oncology, Thoraco Pulmonary Department, National Cancer Institute, Via Mariano Semmola, Naples, Italy
    Anticancer Agents Med Chem 13:844-51. 2013
    ..All patients should be evaluated by a multidisciplinary team, skilled in multimodality treatment and should be counselled about risks and potential benefits of the different therapeutic approaches...
  16. doi request reprint Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
    Raffaele Costanzo
    Thoraco Pulmonary Department, Medical Oncology Unit, Istituto Nazionale Tumori Fondazione G Pascale IRCCS Napoli, Italy
    Expert Rev Anticancer Ther 13:1207-18. 2013
    ..Ongoing and future, well-designed trials should answer all these questions. ..
  17. doi request reprint Vinorelbine for non-small cell lung cancer
    Maria Carmela Piccirillo
    National Cancer Institute, Napoli, Italy
    Expert Opin Drug Saf 9:493-510. 2010
    ..Treatment toxicities are considerable in this setting...
  18. doi request reprint New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development
    Massimo Di Maio
    National Cancer Institute, Clinical Trials Unit, Via Mariano Semmola, 80131 Naples, Italy
    Expert Opin Investig Drugs 19:1503-14. 2010
    ..Most of these drugs offer novel mechanisms of action compared with drugs currently used in clinical practice...
  19. doi request reprint Methodological aspects of lung cancer clinical trials in the era of targeted agents
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Lung Cancer 67:127-35. 2010
    ..In this review, recent aspects of clinical trials methodology in lung cancer are described, and examples of their application are discussed...
  20. doi request reprint Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Department of Medicine and Public Health, Second University of Napoli, Italy
    J Clin Oncol 27:1836-43. 2009
    ..As second-line treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival...
  21. doi request reprint Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Lung Cancer 76:457-64. 2012
    ....
  22. doi request reprint Target-based therapies in breast cancer: current status and future perspectives
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Endocr Relat Cancer 16:675-702. 2009
    ..Therefore, a comprehensive approach that takes into account the complexity of the disease is definitely required to improve the efficacy of target-based therapy in breast cancer...
  23. doi request reprint Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study
    Alessandro Morabito
    National Cancer Institute, G Pascale, Foundation, Via M Semmola, 80131 Napoli, Italy
    Lung Cancer 81:77-83. 2013
    ..89, p = 0.017) and higher response rate (4% vs. 18%, p = 0.19), without substantial increase in toxicity. The addition of cisplatin to single-agent gemcitabine improves survival as first-line treatment of PS2 patients with advanced NSCLC...
  24. ncbi request reprint First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
    Oncologist 12:1288-98. 2007
    ..Beyond indications derived from such studies, there is a great need for more clinical research in this setting...
  25. doi request reprint Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
    Sandro Pignata
    Istituto Nazionale Tumori, Via Mariano Semmola, 80131 Napoli, Italy
    J Clin Oncol 29:3628-35. 2011
    ..Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy...
  26. ncbi request reprint The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lung Cancer 61:67-72. 2008
    ..Aim of this study is to describe activity and toxicity of single-agent gemcitabine given as prolonged infusion in the treatment of elderly patients with advanced NSCLC...
  27. doi request reprint Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
    Renato Franco
    Pathology Unit, National Cancer Institute, Pascale Hospital, Naples, Italy
    Expert Rev Anticancer Ther 13:407-20. 2013
    ..The authors summarize the strategies that in the future could overcome these mechanisms of escape...
  28. doi request reprint Induction therapy for lung cancer: sailing across the pillars of Hercules
    Gaetano Rocco
    Lung Cancer Multidisciplinary Team, Division of Thoracic Surgery, Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy
    Thorac Surg Clin 22:67-75, vi. 2012
    ..Ten crucial issues were identified that may have an impact on the approach to patients with locally advanced lung cancer in everyday practice...
  29. ncbi request reprint Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semola, 80131 Naples, Italy
    Oncologist 11:753-64. 2006
    ....
  30. pmc Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
    Sandro Pignata
    Istituto Nazionale Tumori, Napoli, Italy
    BMC Cancer 8:252. 2008
    ..The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer...
  31. ncbi request reprint Hormonal treatment of human hepatocellular carcinoma
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semmola, 80131 Napoli, Italy
    Ann N Y Acad Sci 1089:252-61. 2006
    ..Negative results have been obtained with antiandrogen therapy. In conclusion, hormonal treatment should not be a part of the current management of HCC patients...
  32. ncbi request reprint Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
    Cesare Gridelli
    Medical Oncology, S Giuseppe Moscati Hospital, Avellino, Italy
    Lancet Oncol 8:500-12. 2007
    ..We aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with first-line treatment with cisplatin plus gemcitabine given by standard infusion...
  33. pmc Time spent for activation of non-profit studies in oncology in Italy
    Gianfranco De Feo
    National Cancer Institute, Naples, Italy
    PLoS ONE 5:e11864. 2010
    ..The aim of this paper is to describe the time spent to activate oncological non-profit clinical trials promoted in Italy by the National Cancer Institute of Naples, following the implementation of recent European laws...
  34. pmc Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
    Ermelinda De Maio
    Clinical Trials Unit, National Cancer Institute, Via M, Semmola, I 80131 Naples, Italy
    BMC Cancer 7:50. 2007
    ....